Trust Co. of Vermont Boosts Stake in Pfizer, Inc. (PFE)

Trust Co. of Vermont increased its stake in Pfizer, Inc. (NYSE:PFE) by 0.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 245,800 shares of the biopharmaceutical company’s stock after buying an additional 2,283 shares during the period. Trust Co. of Vermont’s holdings in Pfizer were worth $8,409,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Cable Hill Partners LLC increased its position in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares in the last quarter. D Orazio & Associates Inc. increased its position in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares in the last quarter. Finally, Acropolis Investment Management LLC increased its position in shares of Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 69.95% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) opened at 33.16 on Tuesday. The stock has a market capitalization of $197.89 billion, a PE ratio of 27.91 and a beta of 1.01. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $36.82. The company’s 50-day moving average is $33.37 and its 200-day moving average is $33.25.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The company had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. The company’s revenue was down 1.7% compared to the same quarter last year. Equities research analysts expect that Pfizer, Inc. will post $2.55 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.86%. Pfizer’s dividend payout ratio (DPR) is 108.48%.

COPYRIGHT VIOLATION WARNING: “[[title]]” was originally reported by [[site]] and is the sole property of of [[site]]. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at [[permalink]].

PFE has been the subject of several recent analyst reports. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 10th. Sanford C. Bernstein reaffirmed a “buy” rating and issued a $35.00 target price on shares of Pfizer in a research note on Monday, April 24th. Barclays PLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. UBS AG reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research note on Monday. Finally, ValuEngine cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $37.68.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).